Compare LONA & STHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LONA | STHO |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.4M | 102.0M |
| IPO Year | N/A | 2022 |
| Metric | LONA | STHO |
|---|---|---|
| Price | $9.29 | $8.88 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 36.3K | 12.1K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $110,143,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.21 | $7.05 |
| 52 Week High | $14.21 | $9.24 |
| Indicator | LONA | STHO |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 60.26 |
| Support Level | $8.10 | $8.26 |
| Resistance Level | $9.88 | $9.02 |
| Average True Range (ATR) | 1.01 | 0.19 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 33.79 | 73.68 |
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.